Lineage Cell Therapeutics Stock Total Debt
| BTX Stock | ILS 218.20 1.20 0.55% |
Lineage Cell Therapeutics fundamentals help investors to digest information that contributes to Lineage Cell's financial success or failures. It also enables traders to predict the movement of Lineage Stock. The fundamental analysis module provides a way to measure Lineage Cell's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lineage Cell stock.
Lineage |
Lineage Cell Therapeutics Company Total Debt Analysis
Lineage Cell's Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Lineage Cell Total Debt | 5.09 M |
Most of Lineage Cell's fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lineage Cell Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Lineage Cell Therapeutics has a Total Debt of 5.09 M. This is 99.81% lower than that of the Healthcare sector and 98.43% lower than that of the Biotechnology industry. The total debt for all Israel stocks is 99.9% higher than that of the company.
Lineage Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lineage Cell's direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lineage Cell could also be used in its relative valuation, which is a method of valuing Lineage Cell by comparing valuation metrics of similar companies.Lineage Cell is currently under evaluation in total debt category among its peers.
Lineage Fundamentals
| Price To Book | 1.14 X | |||
| Price To Sales | 39.20 X | |||
| Revenue | 4.99 M | |||
| Gross Profit | 4.69 M | |||
| EBITDA | (37.2 M) | |||
| Net Income | (45.99 M) | |||
| Cash And Equivalents | 27.1 M | |||
| Cash Per Share | 0.18 X | |||
| Total Debt | 5.09 M | |||
| Debt To Equity | 3.10 % | |||
| Current Ratio | 3.51 X | |||
| Book Value Per Share | 1.09 X | |||
| Cash Flow From Operations | (30.88 M) | |||
| Number Of Employees | 76 | |||
| Beta | 2.87 | |||
| Market Capitalization | 512.15 M | |||
| Total Asset | 101.66 M | |||
| Z Score | 60.0 | |||
| Net Asset | 101.66 M |
About Lineage Cell Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lineage Cell Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lineage Cell using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lineage Cell Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Lineage Stock
When determining whether Lineage Cell Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lineage Cell's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lineage Cell Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lineage Cell Therapeutics Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Lineage Cell Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .